Related Experiment Video
Updated: Feb 24, 2026
09:25
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
19.7K
Survival changes in Patients with Synovial Sarcoma, 1983-2012
Shuncong Wang1, Rongfeng Song2, Tiantian Sun3
1Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China.
Journal of Cancer
|August 19, 2017
Summary
Incidence of synovial sarcoma (SyS) is increasing, yet patient survival rates have not improved over three decades. This highlights an urgent need for better diagnosis, awareness, and novel treatments for this rare cancer.
Area of Science:
- Oncology
- Epidemiology
- Medical Statistics
Background:
- Synovial sarcoma (SyS) is a rare extremity malignancy predominantly affecting adolescents.
- Large-scale population-based studies on SyS incidence and survival trends are limited.
Purpose of the Study:
- To analyze trends in SyS incidence and survival over three decades (1983-2012).
- To identify disparities in survival based on demographic and clinical factors.
Main Methods:
- Utilized data from the Surveillance, Epidemiology, and End Results (SEER) database for 2,070 SyS cases.
- Employed Kaplan-Meier curves to compare survival rates across different decades, age groups, sexes, races, pathological types, stages, and socioeconomic statuses (SES).
Main Results:
- SyS incidence increased significantly from 0.906 to 1.548 per 1,000,000 population.
- Five-year survival rates remained stagnant (69.4% to 60.5%) across the three decades (p > 0.05).
- Observed widening survival disparities among different demographic and clinical subgroups.
Conclusions:
- Despite rising incidence, SyS patient survival has not improved over 30 years.
- There is a critical need for enhanced diagnostic methods and increased healthcare provider awareness.
- Development of novel therapeutic strategies for synovial sarcoma is imperative.
Related Concept Videos
01:21Cancer Survival Analysis
796
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
796
02:07Tumor Progression
7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
01:03Rous Sarcoma Virus (RSV) and Cancer
6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.5K
01:09Changes in the Appendicular Skeleton with Age
3.8K
The upper and lower limb initially develops as a small bulge called a limb bud, which appears on the lateral side of the early embryo. The upper limb bud appears near the end of the fourth week of development, with the lower limb bud appearing shortly after.
Initially, the limb buds consist of a core of mesenchyme covered by a layer of ectoderm. The ectoderm at the end of the limb bud thickens to form a narrow crest called the apical ectodermal ridge. This ridge stimulates the underlying...
Initially, the limb buds consist of a core of mesenchyme covered by a layer of ectoderm. The ectoderm at the end of the limb bud thickens to form a narrow crest called the apical ectodermal ridge. This ridge stimulates the underlying...
3.8K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K